Key result
New direct oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, provide an effective and safe alternative to warfarin for preventing stroke and systemic embolism in non-rheumatic atrial fibrillation.
Why the study?
Do new oral anticoagulants prevent stroke and thromboembolic events in patients with non-rheumatic atrial fibrillation compared to vitamin K antagonists?
Do new oral anticoagulants prevent stroke and thromboembolic events in patients with non-rheumatic atrial fibrillation compared to vitamin K antagonists?
Direct oral anticoagulants represent a significant advancement over vitamin K antagonists for stroke prevention in patients with non-rheumatic atrial fibrillation.
May support DOAC preference in non-rheumatic AF; leaves open head-to-head comparisons and long-term real-world data.
It is known that non-rheumatic atrial fibrillation (AF) is one of the most common types of cardiac arrhythmia and a common cause of cardiogenic cerebral embolism. Oral anticoagulant therapy is a leader in the prevention of thromboembolic events in AF. More than 60 years, only warfarin and other vitamin K antagonists (VKA) were used as oral therapy due to their extraordinary efficacy in preventing stroke and other thromboembolic events after myocardial infarction in AF and prosthetic heart valves. In addition, there are numerous problems associated with treatment with VKA, which significantly limits their widespread use. New anticoagulants, such as the oral direct thrombin inhibitor (dabigatrana etexilate) and the direct factor Xa antagonists rivaroxaban, apixaban, edoxaban, have been recently designed, clinically tested, and put into practice. The initiation of clinical use of these agents has opened up a new page of oral anticoagulant therapy in the prevention of thromboembolic events in AF.
No takes yet. Share an insight, caveat, or question.
Fonyakin et al. (2012) conducted a review in Non-rheumatic atrial fibrillation. Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated. New direct oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, provide an effective and safe alternative to warfarin for preventing stroke and systemic embolism in non-rheumatic atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: